Homepage Top Section1

The approval process was accelerated after Partner Therapeutics received the FDA Commissioner’s National Priority Voucher. Bizengri has already received breakthrough therapy and orphan drug designations for this indication.

The designation recognises the potential of RTx-015 to address significant unmet medical needs in patients with severe retinal degeneration. It advances the therapy’s regulatory support following a regenerative

The approval allows adults with SLE on standard therapy to inject Saphnelo themselves. It is supported by results from the Phase III TULIP-SC trial, which demonstrated that subcutaneous

Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix’s expertise in radiopharmaceutical platforms, global

According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets. C4 Therapeutics will use its TORPEDO platform for

The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial

Supported by Enterprise Singapore, the initiative aims to enhance Biophytis’ computational longevity platform and develop therapies for age-related diseases such as sarcopenia. The collaboration builds on Biophytis’ ongoing

The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low-

This marks the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage. JS001sc is independently developed by Junshi Biosciences as a subcutaneous